NG-641

AXP000039.1 · Oncolytic virus

Platform
adenovirus (Ad11p/Ad3 group B chimera, T-SIGn vector)
Originator
PsiOxus Therapeutics
Sponsor
Akamis Bio

Names

NameTypeSource
NG-641preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 11 (NCBI Taxonomy 10541)
Strain
Ad11p/Ad3 group B chimera (T-SIGn)
Replication
conditionally replicating
Modifications
enadenotucirev backbone carrying a multi-transgene cassette
Transgenes
FAP-TAc bispecific T-cell activator, CXCL9, CXCL10, IFNA2
Route
intravenous, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C168790

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05043714Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursCompletedPhase 12021-12-012023-11-1330Epithelial Tumor; Metastatic Cancer
NCT04830592A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckCompletedPhase 12021-11-042023-12-0736Squamous Cell Carcinoma of the Head and Neck
NCT04053283First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral VectorCompletedPhase 12020-01-232023-08-31186Epithelial Tumor; Metastatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 36897458A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.Investigational new drugs2023cited by trial NCT04053283

Notes

Enadenotucirev backbone armed with a FAP/CD3 bispecific T-cell activator (FAP-TAc) plus CXCL9, CXCL10 and interferon alpha.

How to cite

NG-641 (AXP000039.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000039.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.